Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, fully integrated pharmaceutical company headquartered at Mumbai, India.
The Company is a leader in India in the discovery of new molecules (Both NCES and Biologics) and is focused in the areas of inflammation [Asthma/COPD, etc] and metabolic disorders [Diabetes, Obesity, etc].
Glenmark Generics Limited (GGL), is a subsidiary of Glenmark Pharmaceuticals Limited (GPL) that aims to be a global integrated generic and API leader. GGL has an established presence in North America, EU and Argentina and maintains marketing front-ends in these countries. GGL has a strong base in Formulations development with teams operating out of laboratories in India and Latin America.
Glenmark has been one of the fastest growing Indian formulation companies and is ranked 26 [ORG IMS, March 2008] in the domestic landscape.
About the Audit
The audit on Glenmark Pharmaceuticals Ltd. was performed on 15 – 16 September 2008. The Report is 42 pages long, excluding appendices. Including appendices the Report is 85 pages long.
The Audit Report provides information on the site facilities and covers a wide range of materials, including; Amiodarone Hydrochloride, Cilostazol, Fluconazole, Moexipril Hydrochloride, Bupropion Hydrochloride, Topiramate, Glimepiride, Zonisamide, Itraconazole, Loratadine, Terbinafine Hydrochloride, Oxcarbazepine, Atovaquone, Tazarotene, Lercanidipine (Form-V), Tadalafil, Butenafine Hydrochloride, Atovaquone, Zolmitriptan, Solifenacin succinate, Darifenacin, Perindopril Erbumine, Trandolapril, Esomeprazole, Zolpidem Tartrate, Lercanidipine Hydrochloride, Olmesartan Medoxomil, Adapalene, Cilazapril, Desloratidine, Alfuzosin, GRC-8200, Simvastatin, Rosuvastatine Calcium, Esomeprazole Potassium, Eszopiclone, GRC-6211, Terbinafine Hydrochloride, Esomprazole Mg, Voriconazole, Aprepitant, Ropinrole, Ezetimibe, Frovatriptan, Imiquimod, Riluzole, Tadalafil,Darifenacin, Linezolid, Ezetimibe, Telmisartan.